← All indications
Leukemia, Lymphoid
Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.
Subtype terms (5)
More specific conditions that are subtypes of Leukemia, Lymphoid in the MeSH hierarchy.
- Leukemia, B-Cell
121 drugs (47 approved, 74 experimental)
- Leukemia, Biphenotypic, Acute
68 drugs (51 approved, 17 experimental)
- Leukemia, Prolymphocytic
69 drugs (47 approved, 22 experimental)
- Leukemia, T-Cell
37 drugs (25 approved, 12 experimental)
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
397 drugs (185 approved, 212 experimental)
Drugs by status
Approved for this indication (3)
Phase 4 trials (23)
Phase 3 trials (16)
Phase 2 trials (71)
- 90y-epratuzumab tetraxetan
- acalabrutinib
- acp-319
- pegylated arginine deiminase
- plerixafor
- bendamustine
- epoetin
- moxetumomab pasudotox
- lenalidomide
- clofarabine
- doxorubicin
- tacrolimus
- hemopoietic stem cell
- aldesleukin
- idarubicin
- imtox-25
- Filgrastim
- inotuzumab ozogamicin
- lirilumab
- ms-553
- navitoclax
- allogeneic stem cells
- vitamin c
- ofatumumab
- oshadi d
- ots167
- allogeneic hematopoietic stem cells
- ruxolitinib
- sch66336
- sirolimus
- +41 more
Phase 1 trials (35)
- melatonin
- 19-28z t cells
- azacitidine
- tioguanine
- abt-751
- carfilzomib
- duvelisib
- enzastaurin
- fosfomycin
- hydrocortisone
- bc8
- neovax
- palbociclib
- pegaspargase
- ganetespib
- tg02
- autologous cd34+ cells
- autologous umbilical cord blood
- cd19.car-cd28z t cells
- mesna
- methotrexate
- mab-216
- dexamethasone
- tagraxofusp-erzs
- cd19.car-ankt cells
- cd123 car-t cells
- rgi-2001
- t-allo10
- cyc140
- allogeneic cd34+ cells
- +5 more
Organizations
Organization Involved with Phase 4 Indications (63)
- Astex Pharmaceuticals, Inc.
- Medical Research Council
- J. W. Goethe University
- Universidad Autonoma de Barcelona
- German Federal Ministry of Education and Research
- Pfizer
- University of Arizona
- Shenzhen University
- GlaxoSmithKline
- Chinese Academy of Medical Sciences
- National Cancer Institute (NCI)
- Pharmatech
- Zhengzhou University
- PETHEMA Foundation
- Astellas
- Nordic Society for Pediatric Hematology and Oncology
- Guangzhou Medical University
- Genmab
- Jiangxi Children's Hospital
- Associazione Italiana Ematologia Oncologia Pediatrica
- Qingdao University
- Amgen
- St. Jude Children's Hospital
- Soochow University
- Huazhong University of Science and Technology
- Shantou University
- Deutsche Krebshilfe e.V.
- Shandong Provincial Hospital
- East Valley Hematology and Oncology Medical Group
- University of Vienna
- +33 more
Organization Involved with Phase 3 Indications (180)
- Verastem, Inc.
- The Swedish Research Council
- ERYtech Pharma
- Napo Pharmaceuticals
- Utrecht University
- Bristol-Myers Squibb
- Beijing InnoCare Pharma Tech Co., Ltd.
- Spectrum Pharmaceuticals
- University of Montreal
- Poznan University
- University of Rome Tor Vergata
- Medical College of Wisconsin
- University of Paris
- University of Guadalajara
- Med. Klinik III, Klinikum Leverkusen gGmbH, Germany
- Eastern Cooperative Oncology Group
- Hoosier Cancer Research Network
- Northern Italy Leukemia Group
- Children's Cancer and Leukaemia Group
- University of Cologne
- Cook Children's Medical Center
- San Jorge Children's Hospital, Puerto Rico
- Erasmus University Rotterdam
- University of Toulouse
- Albert Einstein Israelite Hospital
- University of Florence
- Temple University
- Akdeniz University
- Novartis
- Universidad Carlos III Madrid
- +150 more
Organization Involved with Phase 2 Indications (326)
- St. Baldrick's Foundation
- Cephalon
- Azienda Ospedaliera Antonio Cardarelli
- Indiana University
- University of Tuebingen
- Precision BioSciences, Inc.
- Wake Forest University
- DKMS Stiftung Leben Spenden
- Ludwig Maximilians University
- Acrotech Biopharma LLC
- University of Alabama, Birmingham
- OSI Pharmaceuticals
- CHU Mont-Godinne
- Universita Degli Studi La Sapeinza
- Newcastle University
- University of California, Davis
- Fundació Sant Joan de Déu
- Technical University of Dresden
- Chonnam National University
- Academic and Community Cancer Research United
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- Centre Leon Berard
- First People's Hospital of Foshan
- Regione Lombardia
- Kansas Bioscience Authority
- Department of Health, United Kingdom
- Chu De Liège
- Ospedale di Bergamo
- Istitutp di Ematologia ed Oncologia Medica
- Edwards Foundation, Inc.
- +296 more
Organization Involved with Phase 1 Indications (102)
- miRagen Therapeutics, Inc.
- Sungkyunkwan University
- Gemin X
- Xencor
- Texas Tech University
- Intrexon
- Inatherys
- Regimmune Inc.
- VelosBio
- Hrain Biotechnology Co., Ltd.
- Hebei Senlang Biotechnology Inc., Ltd.
- Applied Physiology Research Center
- Tehran University of Medical Science
- Chiltern International
- Orca Biosystems, Inc.
- Children's Hospital Los Angeles
- MediGene
- University of Lorraine
- Wenzhou Medical University
- Dartmouth University
- Erimos Pharmaceuticals
- Department of Defense
- Xeme Biopharma Inc.
- MingSight Pharmaceuticals Pty Limited
- Wyeth
- Neon Therapeutics
- Corixa
- ArQule
- Alex's Lemonade Stand Foundation
- Seyyed-alshohada hospital of Isfahan
- +72 more
Organization Involved with Other Experimental Indications (15)
- Leukosite
- University of Peloponnese
- Thermo Fisher Scientific
- National Autonomous University of Mexico
- All India Institute of Medical Sciences
- Children's Cancer Research Fund United States
- Tawam Hospital
- West Virginia University
- Harokopio University
- University of Illinois at Chicago
- University of Southern Denmark
- University of Cincinnati
- University of Athens
- American Society of Clinical Oncology
- Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon